AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected ...

Q4 2025 Earnings Call Transcript July 15, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.13. Operator: Good morning, and welcome to the ...

A Capital Region manufacturer expects to continue growing its revenue over the next year, though its bottom line could take a ...

AngioDynamics Inc (ANGO) reports a robust 12% revenue increase, driven by Med Tech advancements, despite facing tariff impacts.

Gain insights into AngioDynamics' Q4 2025 earnings, highlighting 12% revenue growth, international expansion, Med Tech advances, and a strong FY26 outlook.

(ANGO) on Tuesday reported a loss of $6.1 million in its fiscal fourth quarter. The Latham, New York-based company said it had a loss of ...

Analysts estimate that AngioDynamics will report an earnings per share (EPS) of $-0.12. Investors in AngioDynamics are eagerly awaiting the company's announcement, hoping for news of surpassing ...

Medical technology company AngioDynamics Inc is bucking what it calls an "extraordinary" effort by a rival company to recover hundreds of thousands of dollars in legal costs following its win at ...

QUEENSBURY -- Queensbury-based medical device manufacturer AngioDynamics Inc. said Tuesday afternoon it expects to be in its new headquarters building in Latham by early spring. The company ...

AngioDynamics's reported results and guidance weren't as bad as the share price reaction would suggest. Read why I rate ANGO stock a Hold.